Effect of Metformin on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Review

doi:10.3969/j.issn.1673-5765.2021.04.015

Abstract

Abstract:

Metformin is the first-line therapeutic drug for type 2 diabetes mellitus (T2DM). In addition to lowering blood glucose, studies have shown that it has an effect on the risk of cardiovascular events in T2DM patients. Compared with other glucose-lowering agents, metformin monotherapy was associated with lowering risk of cardiovascular events in T2DM patients. Metformin-based combination therapy has different effects on cardiovascular risk of T2DM patients. Metformin does not increase the risk of cardiovascular events in T2DM patients with mild renal impairment, while it may be associated with a higher risk of stroke and all-cause mortality in T2DM patients with renal failure.

Key words: Metformin; Cardiovascular events; Stroke

摘要：

二甲双胍是2型糖尿病（type 2 diabetes mellitus, T2DM）的一线降糖药物，除了降低血糖外，研究显示其可能对T2DM患者的心血管事件风险有一定影响。与其他降糖药相比，单用二甲双胍可降低T2DM患者心血管事件的风险；另外，二甲双胍与其他降糖药物联合使用时，对患者的心血管风险也有不同的影响。在肾功能轻度减退的T2DM患者中应用二甲双胍不会增加心血管事件风险，但对于肾功能衰竭的患者，应用二甲双胍可能与较高的卒中和全因死亡风险有关。

关键词: 二甲双胍; 心血管事件; 卒中

ZHANG Min,LI Hong-Wei, SUI Chang-Bai, GAO Yue, ZHAO Yong-Mei, XU Li-Xia, MENG Xia. Effect of Metformin on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Review[J]. Chinese Journal of Stroke, 2021, 16(04): 408-412.

张敏，李洪伟，隋长百，高越，赵咏梅，徐丽霞，孟霞. 二甲双胍对2型糖尿病患者心血管事件的影响[J]. 中国卒中杂志, 2021, 16(04): 408-412.

References

[1] MCCORMICK M T，MUIR K W，GRAY C S，et

al. Management of hyperglycemia in acute stroke：

how，when，and for whom?[J]. Stroke，2008，39（7）：

2177-2185.

[2] TURNER R C，MILLNS H，NEIL H A，et al. Risk

factors for coronary artery disease in non-insulin

dependent diabetes mellitus：United Kingdom

prospective diabetes study（UKPDS：23）[J]. BMJ，

1998，316（7134）：823-828.

[3] SINGH M，ARORA R，KODUMURI V，et al.

Coronary revascularization in diabetic patients：

current state of evidence[J]. Exp Clin Cardiol，2011，

16（1）：16-22.

[4] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2019（中

文版）（2）[J]. 中国卒中杂志，2020，15（11）：1145-

1155.

[5] DOYLE-DELGADO K，CHAMBERLAIN J J，

SHUBROOK J H，et al. Pharmacologic approaches

to glycemic treatment of type 2 diabetes：synopsis of

the 2020 American Diabetes Association's standards

of medical care in diabetes clinical guideline[J]. Ann

Intern Med，2020，173（10）：813-821.

[6] DAVIES M J，D'ALESSIO D A，FRADKIN J，et

al. Management of hyperglycemia in type 2 diabetes，

2018. A consensus report by the American Diabetes

Association（ADA）and the European Association

for the Study of Diabetes（EASD）[J]. Diabetes Care，

2018，41（12）：2669-2701.

[7] CHENG Y Y，LEU H B，CHEN T J，et al.

Metformin-inclusive therapy reduces the risk of

stroke in patients with diabetes：a 4-year follow-up

study[J/OL]. J Stroke Cerebrovasc Dis，2014，23（2）：

e99-105[2020-08-26]. https：//doi.org/10.1016/j.jstrok

ecerebrovasdis.2013.09.001.

[8] ROUMIE C L，HUNG A M，GREEVY R A，et

al. Comparative effectiveness of sulfonylurea and

metformin monotherapy on cardiovascular events

in type 2 diabetes mellitus：a cohort study[J]. Ann

Intern Med，2012，157（9）：601-610.

[9] GRIFFIN S J，LEAVER J K，IRVING G J. Impact

of metformin on cardiovascular disease：a metaanalysis

of randomised trials among people with

type 2 diabetes[J]. Diabetologia，2017，60（9）：

1620-1629.

[10] EKSTRöM N，SCHIöLER L，SVENSSON A-M，et

al. Effectiveness and safety of metformin in 51 675

patients with type 2 diabetes and different levels

of renal function：a cohort study from the Swedish

National Diabetes Register[J/OL]. BMJ Open，2012，

2（4）：e001076[2020-08-26]. https：//doi.org/10.

1136/bmjopen-2012-001076.

[11] GNESIN F，THUESEN A C B，KäHLER L K A，et

al. Metformin monotherapy for adults with type 2

diabetes mellitus[J/OL]. Cochrane Database Syst Rev，

2020，6（6）：CD012906[2020-08-26]. https：//doi.

org/10.1002/14651858.CD012906.pub2.

[12] OU S M，SHIH C J，CHAO P W，et al. Effects on

clinical outcomes of adding dipeptidyl peptidase-4

inhibitors versus sulfonylureas to metformin therapy

in patients with type 2 diabetes mellitus[J]. Ann

Intern Med，2015，163（9）：663-672.

[13] VACCARO O，MASULLI M，NICOLUCCI A，et al.

Effects on the incidence of cardiovascular events of

the addition of pioglitazone versus sulfonylureas in

patients with type 2 diabetes inadequately controlled

with metformin（TOSCA. IT）：a randomised，

multicentre trial[J]. Lancet Diabetes Endocrinol，2017，5（11）：887-897.

[14] ROUMIE C L，GREEVY R A，GRIJALVA C G，et

al. Association between intensification of metformin

treatment with insulin vs sulfonylureas and

cardiovascular events and all-cause mortality among

patients with diabetes[J]. JAMA，2014，311（22）：

2288-2296.

[15] BROMAGE D I，GODEC T R，PUJADESRODRIGUEZ

M，et al. Metformin use and

cardiovascular outcomes after acute myocardial

infarction in patients with type 2 diabetes：a cohort

study[J]. Cardiovasc Diabetol，2019，18（1）：168.

[16] HAN Y C，XIE H Z，LIU Y T，et al. Effect of

metformin on all-cause and cardiovascular mortality

in patients with coronary artery diseases：a

systematic review and an updated meta-analysis[J].

Cardiovasc Diabetol，2019，18（1）：96.

[17] ROUMIE C L，CHIPMAN J，MIN J Y，et

al. Association of treatment with metformin vs

sulfonylurea with major adverse cardiovascular

events among patients with diabetes and reduced

kidney function[J]. JAMA，2019，322（12）：1-11.

[18] CHIEN L N，CHOU C L，CHEN H H，et al.

Association between stroke risk and metformin use

in hemodialysis patients with diabetes mellitus：a

nested case-control study[J/OL]. J Am Heart Assoc，

2017，6（11）：e007611[2020-08-26]. https：//doi.

org/10.1161/jaha.117.007611.

[19] HUNG S C，CHANG Y K，LIU J S，et al.

Metformin use and mortality in patients with

advanced chronic kidney disease：national，

retrospective，observational，cohort study[J]. Lancet

Diabetes Endocrinol，2015，3（8）：605-614.

[20] FDA Drug Safety Communication. FDA Drug Safety

Communication：FDA revises warnings regarding

use of the diabetes medicine metformin in certain

patients with reduced kidney function[EB/OL].

（2017-11-14）[2020-08-26]. https：//www.fda.gov/

drugs/drug-safety-and-availability/fda-drug-safetycommunication-

fda-revises-warnings-regardinguse-

diabetes-medicine-metformin-certain.

[21] Kidney Disease：Improving Global Outcomes

（KDIGO）Diabetes Work Group. KDIGO 2020

clinical practice guideline for diabetes management

in chronic kidney disease[J/OL]. Kidney Int，

2020，98（4S）：S1-S115[2020-08-26]. https：//doi.

org/10.1016/j. kint.2020.06.019.

[22] 中华医学会糖尿病学分会微血管并发症学组. 中国

糖尿病肾脏疾病防治临床指南[J]. 中华糖尿病杂志，

2019，11（1）：15-28.